405 related articles for article (PubMed ID: 11878901)
21. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
Kulski JK; Sadleir JW; Kelsall SR; Cicchini MS; Shellam G; Peng SW; Qi YM; Galloway DA; Zhou J; Frazer IH
Virology; 1998 Apr; 243(2):275-82. PubMed ID: 9568027
[TBL] [Abstract][Full Text] [Related]
22. Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.
Reddy KJ; Banapour B; Anderson DE; Lee SH; Marquez JP; Carlos MP; Torres JV
Immunology; 2004 Jun; 112(2):321-7. PubMed ID: 15147575
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
[TBL] [Abstract][Full Text] [Related]
24. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
Culp TD; Spatz CM; Reed CA; Christensen ND
Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
[TBL] [Abstract][Full Text] [Related]
25. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.
Carter JJ; Wipf GC; Madeleine MM; Schwartz SM; Koutsky LA; Galloway DA
J Virol; 2006 May; 80(10):4664-72. PubMed ID: 16641259
[TBL] [Abstract][Full Text] [Related]
26. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
27. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.
Ludmerer SW; Benincasa D; Mark GE
J Virol; 1996 Jul; 70(7):4791-4. PubMed ID: 8676509
[TBL] [Abstract][Full Text] [Related]
28. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
[TBL] [Abstract][Full Text] [Related]
29. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
[TBL] [Abstract][Full Text] [Related]
30. Immunological analyses of human papillomavirus capsids.
Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
[TBL] [Abstract][Full Text] [Related]
31. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
32. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
33. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
34. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
35. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
Chen Y; Ghim SJ; Jenson AB; Schlegel R
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2137-46. PubMed ID: 9747722
[TBL] [Abstract][Full Text] [Related]
36. Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA.
Rommel O; Dillner J; Fligge C; Bergsdorf C; Wang X; Selinka HC; Sapp M
J Med Virol; 2005 Jan; 75(1):114-21. PubMed ID: 15543569
[TBL] [Abstract][Full Text] [Related]
37. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
[TBL] [Abstract][Full Text] [Related]
38. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.
Orozco JJ; Carter JJ; Koutsky LA; Galloway DA
J Virol; 2005 Aug; 79(15):9503-14. PubMed ID: 16014913
[TBL] [Abstract][Full Text] [Related]
39. Development of a non-denaturing electrophoresis system for characterization of neutralizing epitopes on HPV virus-like particles.
Studentsov YY; Burk RD
J Virol Methods; 2007 Feb; 139(2):208-19. PubMed ID: 17137641
[TBL] [Abstract][Full Text] [Related]
40. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
Christensen ND; Reed CA; Cladel NM
Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
